The long-term status of the trade dispute with China remains unclear, but a 90-day reduction in stratospheric tariffs imposed by the U.S. and China on their respective products provides breathing room for the med-tech companies predicting the hardest hit from the original levels.
Bracco Imaging SpA and Sonothera Inc. have entered into an agreement under which Bracco Imaging will provide its cutting-edge gas-filled microbubbles technology platform to Sonothera for use in the development of its novel, ultrasound-guided nonviral gene therapy platform.
Surgvision GmbH received U.S. FDA 510(k) clearance for the Explorer Air II which will be deployed with pafolacianine, during intraoperative fluorescence imaging. The Explorer Air II will support surgeons in their battle to fight cancer, especially in cases of incomplete resection, as paired with pafolacianine, an imaging agent, it will help them improve tumor visualization and outcomes.
Diagnostic imaging group Bracco Imaging SpA signed a licensing and collaboration agreement with Philochem AG. The companies will focus on developing and commercializing a small molecule for diagnostic imaging applications that can detect metastatic solid tumors in cancer patients.
Bracco Imaging SpA. is buying prostate cancer imaging specialist Blue Earth Diagnostics Ltd. for $450 million, acquiring full rights to Axumin (F18-fluciclovine), a PET radiocontrast agent originally developed by Chicago-based GE Healthcare.